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Tumor necrosis factor (TNF) originally described to causehemorrhagic necrosis
(HN)t oftumors (1, 2), has also been associated with several other important effects
(3, 4). For example, cachexia, which can develop in chronically infected animals,
has been shown to be dependent upon cachectin (5, 6), a substance that was later
found to be identical to TNF (7). Furthermore, shock occurring in animals with
septicemia or in animals exposed to endotoxin has been shown to require TNF (8,
9). While these findings demonstrate that TNF can have detrimental effects under
certain conditions, a primary, beneficial role ofTNF may be in the defense ofthe
host against infections. For example, the damage ofvessels by TNF observed at the
site ofbacterial infection may represent a defense mechanism capable ofstopping
local blood circulation and, thereby, the dissemination oftoxins andbacteria in the
host (10). Thus, systemic toxicity and lethal shock would only occurwhen this first
line of defense breaks down.
The induction ofHN inthe skinofmice injected withbacteria and TNF provides
a model for studying this TNFmediated vessel damage (10). Using this model, we
have demonstrated that the interaction of several different products is required for
HN tooccur(10). Inaddition toTNF,twootherfactorswere identified; one, abacterial
component, and the other, an x-ray-sensitive host cell (10). In this paper we provide
several lines of evidence that the complement component C5 also plays a critical
role in the induction of HN by TNF and bacteria.
Materials and Methods
Agents.
￿
Heat-killed CorynebacteriumparvumpurchasedfromBehringDiagnostics(San Diego,
CA) was diluted in nonpyrogenic saline (Invenex Pharmaceuticals, Inc., Melrose Park, IL)
to 10 mg/mlbefore use. HumanTNF(lot L9085AX; Genentech, Inc., SouthSanFrancisco,
CA) had a specific activity of 5.03 x 10' U/mg, asdetermined in a microcytotoxicity assay
using actinomycinD-treated L929 cells as targets with 1 udefined as equaltothe reciprocal
ofthe dilution ofTNF required to kill 50% ofthe target cells, as previously described (11).
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1 Abbreviation used in this paper: HN, hemorrhagic necrosis.
J. Exp. MED. ® The Rockefeller University Press - 0022-1007/88/12/2007/15 $2.00
Volume 168 December 1988 2007-2021
20072008
￿
TUMOR NECROSIS FACTOR AND COMPLEMENT
TNF had an endotoxin level of 0.06 endotoxin units (EU)/mg as measured in the Limulus
amoebocyte lysate assay, in which l EU is equal to 0.1 ng/ml of USP standard Escherchia coli
endotoxin (lot EC5). Zymosan A from Saccharomycescerevisiae (Sigma Chemical Co., St. Louis,
MO) was boiled for 30 min, washed three times with nonpyrogenic saline, and resuspended
to 50 mg/ml before use. Purified cobravenom factor from Naja naja kaouthia (0.5 mg/ml; Sigma
Chemical Co.) was stored at -20°C and diluted in nonpyrogenic saline for use. LPS from
E. coli 0111 :B4 (lot 755012 ; Difco Laboratories, Inc., Detroit, MI) was diluted in nonpyro-
genic saline to 10 mg/ml before use. Mycoplasma orale was passaged by intracellular growth
in vitroand expanded with infected cells for the generation oflysate as previously described (10).
Mice.
￿
6-10-wk-old, pathogen-free, female mice of the C3H/HeN and AKR strains were
purchased from a germ-free-derived, defined floracolony at the Frederick Cancer Research
Institute (Frederick, MD). DBA/2, A/J, B10.D2/o, B10.D2/n, CBA/J, and C3H/HeJ mice
were obtained from TheJackson Laboratory (Bar Harbor, ME). All mice were maintained
in pathogen-free conditions in laminar flow hoods.
Assayfor HN.
￿
Mice were challenged with C. parvum, mycoplasma-infected cell lysates,
or LPS and TNF as described previously (10). Briefly, the lower backs of mice were shaved
and depilated with a chemical depilator (Nair; Carter-Wallace, New York, NY). C. parvum
(400 gg) or mycoplasma-infected cell lysates (10' cells) were co-injected with TNF (10 Ag s.
c.). LPS (100 mg s. c.) was injected, followed 24 h later by TNF (10 jig) at the same site. FIN
was assessed 24 h later either macroscopically, seen as a dark red to black discoloration of
the skin, microscopically, seen as infiltrating leukocytes and extravasation of blood, or by
measuring the retention of "Cr-labeled blood cells (see below).
Quantification ofHN.
￿
In some cases, HN was quantified using a modification of a method
described previously (12). In principle, this assay measures the radioactivity retained in skin
after intravenous injection of "Cr blood cells. Blood for "Cr labeling was collected into
citrate-treated tubes (Becton Dickinson & Co., Rutherford, NJ) from the retroorbital sinus
ofsyngeneic mice. Erythrocytes were washed three times in nonpyrogenic saline before labeling.
To each 0.5 ml of packed blood cells we added 0.5 ml ofnonpyrogenic saline containing 200
uCi of Na25'Cr04 having a specific activity of 300-400 pCi/mg (Amersham Corp., Arlington
Heights, IL). The blood cell suspension was incubated for 60 min at 37°C, washed three
times in nonpyrogenic saline, and resuspended to a final volume of 2.0 ml. Mice were each
injected with 0.25 ml of the "Cr-labeled bloodcell suspension 60 min afterinjection of TNF
and/or other agents. Mice were killed by cervical dislocation 24 h later and 2 x 2 cm square
segments of full thickness skin containing the site of injection in the center were removed.
The pieces of skin were placed into 12 x 75 mm glass tubes (Fisher Scientific, Pittsburgh,
PA) and the amount of labeled bloodcells retained in lesions was determined usinga Micro-
medic ME-plus gamma counter (Micromedic Systems, Horsham, PA). Previous studies (10)
have shown that FIN reaches a maximum at 24 h after co-injection of C. parvum and TNF
and, therefore, all mice were killed for analysis at that time. Results were reported as counts
per minute per skin segment.
Zymosan-activatedMouse Plasma.
￿
Citrate-treated bloodwas obtained from the retroorbital
sinus ofeither "C5-sufficient" (C3H/HeN) or "C5-deficient" (AKR and B10.D2/o) mice. Pooled
C5-sufficient or -deficient blood was centrifuged 500 g for 15 min. Plasma was obtained and
immediately frozen at -20°C until use. Freshly thawed plasma was activated with zymosan
(5 mg/ml) as modified from a method described previously (13). Briefly, plasma was incubated
with zymosan for 2.5 h at 37°C with frequent agitation. At the end of the incubation period,
zymosan was removed by centrifugation and the supernatant (activated plasma) was used
to reconstitute C5-deficient mice. In some experiments, HCl was added to the activated plasma
to a final concentration of 1 N and the precipitated proteins were removed by centrifugation
at 2000 g for 40 min. This acidification step removes a majority of the plasma proteins (13).
Acidified zymosan-activated plasma was dialyzed in small-pore tubing (MWCO 1000; Spec-
trum Medical, Los Angeles, CA) against 0.1 M ammonium formate (pH 7.0) before recon-
stitution of mice or gel filtration chromatography.
Plasma Reconstitution ofC5-deficientMice.
￿
C5-deficient mice co-injected with C. parvum (400
kg s. c.) and TNF (10 gg) were injected 3 h laterslowly with 0.3 ml i.v. ofC5-sufficient mouse
(C3H/HeN) plasma. In some cases, mice were injected intravenously with C5-deficient plasma,ROTHSTEIN ET AL.
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C5-sufficient mouse plasma heat inactivated at 56°C for 30 min, zymosan-activated plasma,
or column fractions obtained from zymosan-activated plasma after gel filtration chromotog-
raphy. Preliminary experiments showed that injection of plasma 3 h after co-injection of
C. parvum and TNF was optimal for reconstituting C5-deficient mice so that they could de-
velop HN.
Hemolytic Complement Assays.
￿
Classical pathway activity ofmouse plasma was determined
by hemolysis of antibody-sensitized rabbit erythrocytes as previously described (14). Guinea
pig anti-rabbit antibody for sensitization of rabbit erythrocyte targets was prepared as previ-
ously described (15). Briefly, samples of plasma were serially diluted in nonsterile 12 x 75
mm culture tubes in 0.1 ml ofVeronal-buffered saline (pH 7.5) containing 5 % glucose (wt/vol),
0.1% gelatin (wt/vol), 1 mM MgC12, 0.15 mM CaC12, and 1 mM NaN3 . An equal volume
of washed sensitized rabbit red cells was added (107 cells/ml) and the mixture was incubated
at room temperature for 30 min. At the end ofincubation, 1.0 ml ofVeronal-buffered saline
containing 0.1% gelatin (wt/vol) and 1 mM EDTA was added and the red cells remaining
unlysed were pelleted by centrifugation. Supernatants were quantified for released hemo-
globin by absorbanceat 412 nm in a spectrophotometer (No. DU-50; Beckman Instruments,
Fullerton, CA). Hemolytic activity was expressed as the reciprocal of the dilution of plasma
required to lyse 50% of the added red cells per milliliter (CH5o). The reduction of C5 ac-
tivity in zymosan-activated plasma was determined by comparing the hemolytic activity of
C5-deficient plasma to which serial dilutions of either zymosan-activated or nonactivated
C5-sufficient plasma had been added. Sensitized red cells were added, incubated for 60 min
at room temperature, and the remaining red cells were pelleted by centrifugation to deter-
mine the amount ofhemolysis as described above. The percent reduction of C5 activity was
calculated by the formula: 100 x [1-(CH5o of zymosan-activated plasmaJCH5o of C5-sufficient
plasma)].
GelFiltration Chromatography.
￿
Bio-gel P60 (Bio-Rad Laboratories, Richmond, CA) was used
to fractionate acidified zymosan-activated C5-sufficient or -deficient mouse plasma. The frac-
tionation range of Bio-gel P60 is 3,000 to 60,000 M, and, therefore, ideal for the isolation
of anaphylatoxins (13). Plasma samples were applied to a 1.5 x 75 cm Bio-gel P60 column
equilibrated in 0.1 M ammonium formate, pH 7 .0. A majority of the high molecular weight
plasma proteins were eluted in the void volume. Single column fractions or pooled fractions
were tested for their capability to reconstitute B10.D2/o mice to respond with HN after co-
injection of C. parvum and TNF.
Results
C5-Deficient Mice Do Not Develop HN when Injected with TNFanda Bacterial Compo-
nent. When comparing various strains of mice for induction of HN by TNF and
C. parvum, LPS, or lysates ofcellsinfected withM. orale, we found that certain strains
of mice consistently failed to develop HN (Table 1, Fig. 1). In search of a genetic
traitshared by these mice, we found that all ofthese nonresponsive strains were those
known to have no detectable levels of C5 in the plasma (18, 19; for review see refer-
ence 20). In contrast, the C5-sufficient CBA, Bl0.D2/n, and C3H mouse strains
regularly developed HN characterized by a round, dark red to black, flat lesion (Fig.
1) involving the full thickness of skin, 0 .5-2.5 cm in diameter (mean diameter, 1.4
cm t 0.1 SEM). These HN lesions could also be quantified in a "Cr-labeled blood
cell assay that had been used previously to quantify HN induced in tumors by TNF
(12). Thus in Fig. 2 ., C5-sufficient mice show significant extravasation of blood cells
as quantified by the retention of "Cr-labeled blood cells in skin with HN. just like
the induction of macroscopic HN, Fig. 2 also shows that this effect required injec-
tion of C. parvum as well as TNF. C5-deficient mice that show no macroscopic HN
also show no significant differences in retention of "Cr-labeled blood cells between
skin injected with C. parvum alone and skin injected with C. parvum and THE These2010 TUMOR NECROSIS FACTOR AND COMPLEMENT
TABLE I
C5-deficient Mouse Strains Fail to Develop HN
when Injected with a Bacterial Agent and TNF
' HN was induced by subcutaneous co-injection of C. parvum and TNF or
M. orate-infected cell lysates and TNF. Alternatively, HN was induced by sub-
cutaneous injection of LPS followed 24 h later by TNF.
t Mice deficient in C3 havelow but detectable levels ofC3 (16, 17). Mice deficient
in C5 have no detectable C5 (18, 19; for review see reference 20).
S Number of mice responding with HN per total number of mice tested. HN
was assessed 24 h after injection of TNF. The mean diameter of the hemor-
rhagic lesions of different C5-sufficient mouse strains was similar (1 .8 cm t
0.2 SEM). Data are pooled from two or more independent experiments, each
containing at least one C5-sufficient and one C5-deficient group of mice.
datacan be corroboratedmicroscopically by demonstratingthat the increased retention
of "Cr-labeled blood cells in skin showing HN is indeed associated with the ex-
travasation ofred blood cells (Fig. 3, D and E). C5-deficient mice show inflamma-
toryinfiltrates butnoevidenceofextravasation ofredcells (Fig. 3, Fand G). There-
fore, these inflammatory whitebloodcellinfiltratesmaybe responsible forthe slightly
increased retention of"Cr-labeled blood cells in the skin of these C5-deficient mice
(Fig. 2). Although this level is increased significantly above the level observed in
noninjected skin, it is much lower than in mice developing HN. Since C5-deficient
mice lack C5a, a potent leukocyte chemoattractant derived from the activation of
C5 (21), one might argue that the failure ofthese mice to develop HN was due to
insufficient leukocyte infiltration. However, C5-deficient mice show equal or even
greater inflammatory infiltrates when compared with C5-sufficient mice (Fig. 3).
Therefore, the failure ofC5-deficient mice to develop HN was not due to the ab-
sence ofa leukocyte infiltrate. Interestingly, B10.D2/n mice did not show the same
high incidence of HN as the other C5-sufficient strains, which responded 90-100%
ofthe time. One known difference is that B10.D2/n mice have a lower level of C3
than the three other C5-sufficient mouse strains (17). Together, these data suggest
thatcomplement components atorbeyond C5 in thecomplement pathwayareneces-
sary, whereas early acting components of the classical (Cl, C2, C4, and C3) and
Bacterial
agent'
Mouse
strain
Complement
deficiency)
Incidence of
HN (%)S
C. parvum C3H/HeN None 13/14(93)
C3H/HcJ None 4/4(100)
CBA/J None 9/10(90)
B10.132/n C3 14/22 (64)
DBA/2 C3, C5 0/10 (0)
B10.132/o C3, C5 0/13 (0)
A/J C5 0/12 (0)
AKR C5 0/7 (0)
LPS C3H/HeN None 11/11 (100)
B10.D2/o C3, C5 0/10(0)
M. orate-infected
cell lysates C3H/HeN None 10/10(100)
DBA/2 C3, C5 0/10(0)ROTHSTEIN ET AL.
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FIGURE 2 . Quantification of
HN developing in C5-sufficient,
but not C5-deficient, mice after
injection ofCparvum andTNF .
C3H/HeN (C5-sufficient) or
B10.D2/o (C5-deficient) mice
were injected with either TNF
(10 ug) alone, heat-killedC par-
vum (400 gg) alone, or heat-
killed C . parvum (400 I+g) and
TNF (10 tug) . 24 h later, reten-
tion of 51Cr blood cells in the
skin was quantified by mea-
suring the radioactivity of a 2
x 2cm square piece ofskin con-
taining the site of injection in
the center. For details see Ma-
terials and Methods. Data are
pooled from three independent
experiments .
the alternative (B, D, P, C3) pathway may contribute, but are not sufficient alone
to cause HN in animals injected with C . parvum and TNF .
Depletion of Complement in C5-sufficient Mice by Cobra Venom Factor (CVF) Prevents the
Induction ofHN . IfC5 was truly needed for the formation ofHN in C5-sufficient
mice, then the depletion ofcomplement should abrogate the capacity of such mice
to respond with HN . CVF isolated from Naja naja kaouthia venom, by generating
a C3/C5-convertase, causes the depletion ofC3 and factor B as well as the depletion
of the terminal (C5-9) components of the complement pathway (22, 23) . Indeed,
C5-sufficient C3H/HeN mice pretreated with two injections of purified CVF (50
lig i.v injections 4h before and, again, at the time ofco-injection ofC . parvum and
TNF) failed to develop HN 24 h later(Exp . 1, 0/4, Exp . 2, 0/4) . In contrast, non-
treated control mice responded with HN (Exp. 1, 4/4, Exp. 2, 4/4) . CVF, however,
didnot prevent leukocyte attraction sinceCVFpretreated mice had as great an influx
of leukocytes as the nontreated mice (data not shown) . These data confirm that the
depletion ofcomplementcomponents in C5-sufficientmice canpreventthedevelop-
ment ofHN .
C5-deficient Mice Can Be Reconstituted with C5-sufficient Plasma to Develop HN .
￿
To
obtain further evidence that the C5 defect in C5-deficient mice was responsible for
their failure to develop HN, C5-deficient mice were reconstituted with plasma from
C5-sufficient mice. Table II shows that such plasma was fullycapableofreconstituting
two different C5-deficient mouse strains, B10.D2/o andAKR. Heat inactivation of
this plasma at 56°C for 30 min abrogated its capacity to reconstitute C5-deficient
mice, a finding consistent with the notion that complement was indeed the active
component . As expected, plasma from C5-deficient mice could not reconsitute
Bl0.D2/o orAKR mice to respond withHN to co-injection ofC . parvum and TNF .
(Table II). These data support the notion that C5 can completely correct the defect
in C5-deficient mice to respond withHN to coinjection ofC . parvum andTHE These
reconstitution experiments also provided us with an assay to identify the specific
complement component required for the induction ofHN .FIGURE 3 .
￿
Inflammatory infiltrate without extravasation ofred blood cells in skin of C5-deficient mice
injected withTNF and C . parvum. (A-E) Skin sections of C5-sufficient C3H/HeN mice. (A) Nonin-
jected . (B)TNF (10 gg) ; no infiltrate . (C) C . parvum (400 gg) ; extensive leukocyte infiltrate. (D andE)
C . parvum (400 gg)andTNF (10 gg) ; extensive leukocyte infiltrate with extravasation of red blood cells.
(F and G) skin sections of C5-deficient A/J mice injected with C . parvum (400 ug) and TNF (10 wg);
extensive leukocyte infiltrate but no red cell extravasation (A-D, F : x 99;E and G x 600).2014
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TABLE If
C5-deficient Mice Can Be Reconstituted with Plasma
from C5-sufficient Mice to Respond with HN
Mice were co-injected with C. parvum and TNF followed by plasma reconsti-
tution 3 h later (for details see Materials and Methods).
C5-sufficient plasma was collected from C3H/HeN mice. C5-deficient plasma
was collected from eitherAKR, DBA/2, or BIO.D2/o mice. C5-sufficient plasma
was heat inactivated (HI) by incubation at 56'C for 30 min.
Retention of5ICr-labeled blood cells in skin of mice isolated 24 h after
Lion of C parvum and TNF. For details see Fig. 2.
Number of mice responding with HN per total number of mice tested. HN
was observed 24 It after reconstitution. The mean diameter ( ± SEM) of the
hemorrhagiclesions was similarbetween strains (1 .8 cm ± 0.3 cm for BIO.D2/0;
and 1.7 cm ± 0.3 cm for AKR). Data are pooled from two or more
dent experiments, each containing a positive control group (C3H/HeN
injected with C, parvum and TNF).
C-
Hemolylic Activity ofAwma 11 WNeeded to Reconstitute C5-deficient Mice to Respond
with HN. Since C5-deficient mice have a selective genetic defect in their ability
to secrete C5 (19, 24, 25), whilehaving normal levels ofallother complementcom-
ponents, two possible pathways involvingC5 in thepathological processofHN could
be proposed : (a) C5 could be activated locally and the active cleavage product C5b
could trigger the assembly ofthe membrane attack complex (C5b-9) which, in the
presence ofleukocytes and TNF, could cause direct vessel damage leading to HN;
or (b)C5 could beactivatedlocally andthe C5-derived fragment C5a, together with
TNF, could interact with infiltrating leukocytes to induce the secretion ofhydrolytic
enzymes, reactive oxygen intermediates, and/or vasoactive substances which ulti-
mately cause vessel damage and HN.
Zymosan can deplete plasma of many ofthe hemolytic components of comple-
tile leaving the anaphylatoxins, Maand C5a, behind (26). Table III shows
that plasma depleted ofdetectable hemolytic activity was still completely capable
ofreconstituting C5-deficient BIO.D2/o mice forthe induction ofHN by C. parvum
and TNE In fact, C5 activity ofzymosan-activated plasma was depleted by 96%
ured in vitro by a hemolytic assay specific for C5 (Table III). These data
suggest that theterminalcomplement components (membraneattack complex) were
not needed for HN to occur. The data are consistent, however, with the
C5a may be the missing component required for C5-deficient mice to develop HN.
Partially Purified C5a and TNF Can Cause HN in C. parvum-treated C5-deficient
C5-deficient Plasma used for Retention of Incidence of
responder* reconstitution) blood in skins HN (%)Q
CPM ± SEM
1310.132/o Sufficient 22,385 8,552 16/17 (94)
Deficient 0/4(0)
Sufficient (HI) 5,474 1,375 0/5 (0)
None 4,105 110 0/5 (0)
AKR Sufficient - 12/14(8(i)
Deficient - 0/4(0)
Sufficient (HI) - 0/3 (0)
None - 0/9(0)ROTHSTEIN ET AL.
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TABLE III
C5-sufficient Plasma Depleted of Hemolytic Activity Can Reconstitute
C5-deficient Mice to Respond with HN
C5-sufficient plasma was either kept at 4°C, incubated for 2.5 h at 37°C, or
incubated at 37°C with 5 mg/ml zymosan for 2.5 h followed by removal of
zymosan by centrifugation.
Hemolytic activity ofplasma was determined using a standard rabbit erythro-
cyte hemolysis assay. CHso values of each sample are reported as U/ml
BEM.
Represents the percent reduction in C5 activity as measured by the capacity
oftreated plasma to reconstitute hemolytic activity in C5-deficient plasma. Data
are reported as percent reduction in CHso from control t BEM. For details
see Materials and Methods.
1110.132/o mice were co-injected with C. 6arvum (400 pg) and TNF (10 pg)
3 h before the start of the experiment and then reconstituted with plasma as
described in the footnote ofTable II. HN was assessed 24 h later and reported
as the number of mice responding with HN per total number of mice tested.
The mean diameter ( t SEM) of the hemorrhagic lesions was similar be-
tween the groups (1 .6 cm t 0.1 cm). Data are pooled from three independent
experiments.
Mice.
￿
Sincemany moleculesotherthan C5aare present in zymosan-activated, C5-
sufficient plasma, we attempted further purification of the active component in
zymosan-activatedplasma whichcouldreconstitute C5-deficient mice.Thus, zymosan-
activated, C5-sufficient and -deficient plasma were acid precipitated to remove un-
wanted plasma proteins without affecting the acid soluble C5a (13). The superna-
tant was dialyzed against 0.1 M ammonium formate and fractionated through a
Bio-Gel P60 column (Fig. 4). Acid-soluble plasma proteins >60,000 Mr eluting in
the void volume had no activity. Pooled smaller sized fractions were tested for their
ability to reconstitute C5-deficient mice to develop HN after injection of C. parvum
and TNF. Fig. 4 and Table IV show that only a pool of fractions corresponding
to proteins within the molecular weight range of 8,000-15,000 could reconstitute
C5-deficient mice for theinduction ofHN . Furtheranalysis ofsingle fractionswithin
this size range revealed that the activity corresponded to aproteinwith aMr of 9,000
(Fig. 4, Table IV). Similarfractions tested from the zymosan-activated C5-deficient
plasma did not reconstitute treated mice. The molecular weight of this acid-stable
protein is consistent with published reports of the molecular weight of rat, guinea
pig, porcine, and human C5a, which ranges from 8,000 to 15,000 (27, 28). These
data further implicate C5a in the induction of HN by C. parvum and TNF.
Discussion
This paper showsthat TNF requires the fifthcomponent ofcomplement in order
to induce hemorrhagicnecrosis in skin exposedto bacterial agents. This is supported
Treatment of
plasma in vitro'
Plasma hemolytic
activity:
U/ml
Reduction of
plasma C5 activitys
Incidence of
HN (%)n
4°C 165 t 15 0 t 0 5/6 (83)
37 0C 103 t 23 51 t 6 7/8 (88)
37 1C + Zymosan <50 t 0 96 ± 2 9/11 (82)2016
￿
TUMOR NECROSIS FACTOR AND COMPLEMENT
_1
E c
0
N
0
00
O
F[GURE 4.
￿
Gelfiltration chro-
matography of acidified zy-
mosan-activated plasma from
C5-sufficient mice. Column frac-
tions were collected andmoni-
tored for total protein at 280
nm. Elution volumes oflow mo
60
￿
80
￿
100
￿
lecular weight standards are
(ml)
￿
shown. Themolecular weights
Volume of ovalbumin (OVA), myglobin
(MYO) and vitamin B12 (B12)
are 44,000, 17,000, and 1,350, respectively. Protein that eluted at a volume corresponding to a
M, of 9,000 reconstituted C5-deficient mice to develop HN when injected with C. parvum and
TNF (filled bar). The open bars represent the relative location of the active single and pooled
fractions tested from two independent gel filtrations, thus confirming this M,.
by several lines of evidence: First, mouse strains that do not have C5 do not develop
HN after injection of TNF and the bacterial agent into skin (Table 1, Figs. 1 and
2). Second, plasma from C5-sufficient mice correctedthe defect in C5-deficient mice
(Table 11). Third, heatingplasma at 56°C for30 mininactivated itscapacity to recon-
stitute the C5-deficient mice, suggesting that complement is the critical component
in theplasma (Table 11). Fourth, CVFtreatmentof mice, known to deplete comple-
ment in vivo, abrogated the ability of C5-sufficient mice to respond.
C5 is known to mediate several biological functions associated with complement
activation: anaphylactic, chemotactic, and leukocyte-activating functions, which re-
quire C5a (Mr of 8,000-15,000) and hemolysis, which requires C5b (Mr of 160,000).
We found that plasma activated with zymosan to enrich for C5a and acidified to
deplete C5 was still fully capable of reconstituting C5-deficient mice. As expected,
such plasma did not cause hemolysis in the presence of appropriate antibody in an
in vitro assay. Finally, only the plasma fraction corresponding to the size range of
C5a reconstituted C5-deficient mice. These findings indicate that C5a and not the
membrane attack complex is required for HN to develop when TNFis injected into
TABLE IV
C5-deficient Mice Reconstituted with a Partially Purified
9, 000Mr Protein Respond with HN
* BIO.D2/o mice were reconstituted with column fractions as described in the
footnote ofTable II. Data are pooled from twoindependent experiments, each
containing as positive control C5-deficient B10.D2/o mice co-injected with
C. parvum andTNFfollowed by reconstitution with unfractionated C5-sufficient
plasma.
Elution volume
MI
M, Incidence of HN (%)'
65-75 11,500-8,000 4/5 (80)
68 10,000 0/4 (0)
71 9,000 2/4 (50)
75 8,000 0/4(0)
78 7,000 0/4(0)
78-100 7,000-4,000 0/3 (0)ROTHSTEIN ET AL.
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skin exposed to bacteria. Our studies do not exclude the fact that earlier comple-
ment components participate in the development of TNFmediated HN. In fact,
C3 is normally required for the generation of C5a and the lower responsiveness of
mouse strains that have reduced levels of C3 (but are sufficient in C5) is consistent
with this. Interestingly, the serum level of C3 is linked to a gene within the MHC
complex (16), which is also where the TNF gene is located (29, 30).
Although C5ais required for theformation ofTNFmediated HN in skin exposed
to bacterial agents, it is likely that the much more stable derivative ofC5a, C5a-des-
arg, is the actual molecule involved in vivo since the terminal arginine residue of
C5a is quickly cleaved off in the serum by carboxypeptidase N (31). In humans,
this derivative is greatly reduced in its biological activity both in vivo and in vitro
andit has completely lost spasmogenic activity (32). In contrast, rodent C5a-des-arg
retains much of the original activity of theparental C5a molecule (27). It is possible,
therefore, that C5a-des-arg behaves the same way as C5a in the HN response de-
scribedhere. At present, we do notknow whether this apparently unique difference
between mouse and humanC5amay explain our inability to reconstitute C5-deficient
mice with human plasma (Rothstein, J. L., unpublished observation).
At present, we do not know through which mechanism C5a participates in the
development of HN. Even though C5a is a potent leukocyte chemoattractant, C5-
deficient and C5-sufficient mouse strains still showed very similarleukocyteinfiltrates
after injection of bacteria. Therefore, is is unlikely that the defect of C5-deficient
mice is related to such a role for Ma. Alternatively, C5a, known to cause vessel
leakage, might directly damage vessels to cause extravasation of blood. However,
this is unlikely since C5aalone when injected intravenouslyor subcutaneously does
not cause HN. Therefore, it is unlikely that C5a is the ultimate mediator of the
tissue damage resulting in the development of HN . Alternatively, C5a and TNF
may be two signals that are required in vivo for infiltrating leukocytes to release
as yet undefinedproducts that are ultimately the mediators of vessel disruption and
hemorrhage. In vitro models are consistent with the idea that, in addition to TNF,
a second signal is required for the release of mediators from neutrophils (33, 34).
We do not know the precise role of the bacterial agent in the development of HN .
It appears that thebacterial component is critical for attracting inflammatory leuko-
cytes. However, this maynot be the only role bacteria play since LPS-resistant mice
that are complement sufficient have normal leukocyte infiltrates after injections of
LPS but do not develop HN after asubsequent injectionof TNF(10). In these mice,
therefore, it is possible that LPS attracts but does not activate leukocytes to become
responsive to mediator release by C5a and TNF.
The HN described here has many similarities with one form of the Shwartzman
phenomenon, thelocalized Shwartzman reaction. It is characterizedby the develop-
ment oflocalized FIN after a sensitizing and eliciting dose of bacterial agents (35).
It is interesting, in this regard, that C6-deficient rabbitsrespondedwith HN to repeated
endotoxin injections which suggests that C5b-9 assembly was also not required for
the localized Shwartzman reaction (36). Other experiments show that anti-C3 an-
tiserum or CVF prevented the development of the localized Shwartzman reaction
(37, 38). Even though theseearly experimentsdid not identify C5aas a critical com-
ponent in the development of HN, these findings are certainly consistent with the
possibility that C5a is required for the localized Shwartzman reaction. The other2018
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form ofthe Shwartzman phenomenon, which is usually referred to as the general-
ized or systemic Shwartzman reaction, probably can account for septic shock, but
interestingly, C5a may not be needed for the pathophysiological events leading to
shock. For example, we found (Rothstein, J. L., and H. Schreiber, unpublished ob-
servations) thatC5-sufficient andC5-deficient mousestrains areequally susceptible
to the synergistic induction ofsystemic shock by intravenous injection ofTNF and
bacterial agents. Furthermore, C6-deficient rabbits are equal or more susceptible
to the induction ofthe generalized form of the Schwartzman reaction (39). HN is
also observed in solid tumors treated with TNF (1) but, in contrast to normal skin
(10), TNF alone will cause this necrosis (1). To this end, it is interesting that tumors
growing in C5-deficient mice are still susceptible to HN induced by TNF (Roth-
stein, J. L., and H. Schreiber, unpublishedobservations). Itis possiblethat thetumors
in these mice supply or elicit a signal similar to that given by C5a.
The disruption ofcapillaries in HN in the vicinity ofbacteria may prevent rapid
spread ofbacteria or their products into the circulation; thus, HN may be part of
an important local defense mechanism. Presumably, TNF would be produced by
the activated macrophagesthat areknowntobepresent in suchlesionsand thecom-
paratively smaller amount ofsecreted TNFwould result in microscopic rather than
macroscopic lesions. The described local response involving C5a, TNF, and bac-
teriamayprovide one explanation forwhy C5-deficient mouse strains haveincreased
susceptibility to certain infections. Such mice are known to be more susceptible to
pneumococcal, staphylococcal, gonococcal, and mycoplasmal infections, although
theyappear tohave intact mechanisms ofchemotaxis(40). In addition, C5-deficient
mice are more susceptible to infections by cryptococcus or candida and are slightly
more susceptible than C5-sufficient mice to infection by intracellular bacteria and
to viral infections such asinfluenza (40). Thus, we proposethat C5a synergizeswith
TNF and leukocytes to cause local vessel disruption and hemorrhage; by this de-
fense mechanism the spread of bacteria and toxins may be prevented.
Summary
TNFinduces hemorrhagicnecrosis (HN) when injected into skin exposed to bac-
terial agents but not when injected into normal skin. In this paper, we present sev-
eral lines ofevidence suggesting that TNF requires the fifth component ofcomple-
ment (C5) to induce HN in skin exposed to bacteria. First, mouse strains that do
not haveC5 did notdevelop FIN afterinjection ofTNF andbacteriainto skin. Second,
plasma from C5-sufficient mice could correct the defect in these C5-deficient mice.
Third, heating at 56°C for 30 min inactivated the capacity ofplasma to reconstitute
C5-deficient mice. Fourth, CVF, which isknown toinactivate complement, abrogated
the capability ofC5-sufficientmice torespond. Fifth, depleting plasma ofhemolytic
activity while generating C5a did not affect the capacity ofthe activated plasma to
reconstitute C5-deficient mice. Finally, only the plasma fraction containing mole-
cules ofthe size range ofC5a reconstituted C5-deficient mice. These findings indi-
cate that C5aand not the membrane attack complex is required for HN. Although
we do not know through which mechanism C5aparticipates in the development of
HN, we propose thatthedescribed HN response is related to alocal defense mecha-
nism in which TNF and C5a lead to the disruption of capillaries in the direct vi-
cinity ofbacteria. By this mechanism the rapid spread ofbacteria or their productsinto the circulation is prevented. Such a tissue response is consistent with the known
higher susceptibility of C5-deficient mice to bacterial infections and provides a model
with which to search for the multiple steps involved in this important local defense
mechanism.
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